InventisBio (SH:688382) Zheng Quan Zhi Xing·2025-07-30 00:07Group 1 - Xin Yuan Fund recently conducted research on a listed company, Yifang Bio, discussing the latest progress of multiple drugs under development [1] - Drug D-2570 is planned for clinical exploration in various autoimmune diseases, with Phase II clinical trials for ulcerative colitis already initiated [1] - The drug Gesorex (brand name Anfangning) is expected to be approved by the National Medical Products Administration for advanced non-small cell lung cancer (NSCLC) patients with KRS G12C mutation by November 2024, with multiple clinical studies ongoing [1] - Drug D-0502 is undergoing Phase III clinical trials both domestically and internationally, showing promising safety and anti-tumor effects [1] - Drug D-0120 has completed Phase IIb clinical trials, while preclinical studies for YF087 and YF550 have made progress [1] Group 2 - Xin Yuan Fund was established in 2013, with a total asset management scale of 212.33 billion yuan, ranking 35th out of 210 [2] - The asset management scale for non-monetary public funds is 140.64 billion yuan, also ranking 35th out of 210 [2] - The fund manages 162 public funds, ranking 47th out of 210, with 22 public fund managers, ranking 63rd out of 210 [2] - The best-performing public fund product in the past year is Xin Yuan Guozheng 2000 Index Enhanced A, with a latest net value of 1.23 and a growth of 60.06% over the past year [2] - The latest public fund product raised by Xin Yuan is Xin Yuan Science and Technology AI Index Initiated A, with a subscription period from July 25, 2025, to August 8, 2025 [2]